| P50 | author | Allan B. Dietz | Q38325991 |
| P2093 | author name string | Yi Lin | |
| | Michael P Gustafson | |
| | Rebecca R Laborde | |
| | Peggy A Bulur | |
| P2860 | cites work | Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer | Q24632187 |
| | Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha | Q28251443 |
| | Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans | Q28511526 |
| | Cancer immunotherapy via dendritic cells | Q29615444 |
| | The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting | Q29618424 |
| | Human dendritic cells adenovirally-engineered to express three defined tumor antigens promote broad adaptive and innate immunity | Q30426385 |
| | A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells | Q33335471 |
| | Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine | Q33584867 |
| | Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. | Q34287902 |
| | Dendritic-cell-based therapeutic cancer vaccines | Q34360094 |
| | Dendritic Cell Function in Vivo during the Steady State: A Role in Peripheral Tolerance | Q35119879 |
| | Association of an increased frequency of CD14+ HLA-DR lo/neg monocytes with decreased time to progression in chronic lymphocytic leukaemia (CLL). | Q36206949 |
| | Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells | Q36369028 |
| | Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity | Q36996588 |
| | Myeloid-derived suppressor cells in parasitic infections | Q37808167 |
| | Immature, Semi-Mature, and Fully Mature Dendritic Cells: Toward a DC-Cancer Cells Interface That Augments Anticancer Immunity | Q38174601 |
| | Monocytic suppressor cells derived from human peripheral blood suppress xenogenic immune reactions | Q39039101 |
| | Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer | Q39188755 |
| | Origin, maturation and antigen presenting function of dendritic cells. | Q40906220 |
| | Dendritic cell development: a choose-your-own-adventure story | Q41610273 |
| | Immune monitoring using the predictive power of immune profiles | Q41684399 |
| | Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone | Q41826343 |
| | Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer | Q42183073 |
| | Immunosuppressive CD14+HLA-DR(low)/- monocytes in B-cell non-Hodgkin lymphoma | Q42591459 |
| | Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab | Q44017442 |
| | Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcino | Q45197611 |
| | Immunosuppressive CD14+HLA-DRlow/neg IDO+ myeloid cells in patients following allogeneic hematopoietic stem cell transplantation | Q45750460 |
| | Increased CD14(+)HLA-DR (-/low) myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients. | Q45936373 |
| | Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion | Q46440292 |
| | Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma. | Q46529900 |
| | Effect of prostaglandin E2, lipopolysaccharide, IFN-gamma and cytokines on the generation and function of fast-DC. | Q46615940 |
| | Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines. | Q50669894 |
| | Increase in CD14+HLA-DR -/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis. | Q50909590 |
| | Mycobacterium bovis Bacillus Calmette-Guérin Vaccination Mobilizes Innate Myeloid-Derived Suppressor Cells Restraining In Vivo T Cell Priming via IL-1R–Dependent Nitric Oxide Production | Q59807735 |
| | Identification of a New Subset of Myeloid Suppressor Cells in Peripheral Blood of Melanoma Patients With Modulation by a Granulocyte-Macrophage Colony-Stimulation Factor–Based Antitumor Vaccine | Q60311223 |
| | Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions | Q74179201 |
| | Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign | Q84256128 |
| | Internalization and endosomal degradation of receptor-bound antigens regulate the efficiency of cross presentation by human dendritic cells | Q84569562 |
| | Increased circulating immunosuppressive CD14(+)HLA-DR(-/low) cells correlate with clinical cancer stage and pathological grade in patients with bladder carcinoma | Q85070146 |
| | Increased circulating Lin(-/low) CD33(+) HLA-DR(-) myeloid-derived suppressor cells in hepatocellular carcinoma patients | Q86844134 |
| | Clinical-grade manufacturing of DC from CD14+ precursors: experience from phase I clinical trials in CML and malignant melanoma | Q94433420 |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 147 | |
| P577 | publication date | 2014-04-04 | |
| P1433 | published in | Frontiers in Immunology | Q27723748 |
| P1476 | title | Cancer Vaccines in the World of Immune Suppressive Monocytes (CD14(+)HLA-DR(lo/neg) Cells): The Gateway to Improved Responses | |
| P478 | volume | 5 | |